About the Company
bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world. The company is developing LentiGlobin gene therapy for the treatment of sickle cell disease and cerebral adrenoleukodystrophy. It is also developing T cell product candidates to treat acute myeloid leukemia, Merkel-cell carcinoma, diffuse large B-cell lymphoma, and MAGEA4 solid tumors.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BLUE News
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Shareholders
NDAQ:BLUE) Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Shareholders ...
bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
SOMERVILLE, Mass., May 06, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m.
Lost Money on bluebird bio, Inc.(BLUE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
THE LAWSUIT: A class action securities lawsuit was filed against bluebird bio, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between ...
Shareholders That Lost Money on bluebird bio, Inc.(BLUE) Should Contact Levi & Korsinsky About Pending Class Action - BLUE
NDAQ:BLUE) Shareholders That Lost Money on bluebird bio, Inc.(BLUE) Should Contact Levi & Korsinsky About Pending Class ...
Levi & Korsinsky Notifies Shareholders of bluebird bio, Inc.(BLUE) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / May 3, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, ...
bluebird bio Inc BLUE
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...